BenchSci
BenchSci provides an AI-powered platform for biomedical research. Its flagship product, ASCEND, helps scientists discover biological connections and optimize experiments.
Secondary Market Price
How BenchSci Measures Up
To help you manage your BenchSci equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series D
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of BenchSci's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future BenchSci Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for BenchSci's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
BenchSci, also known as Scinapsis Analytics, provides an artificial intelligence platform for preclinical research and development in the biomedical industry. The company’s main offering is ASCEND, a neuro-symbolic AI platform that integrates a client's internal data with public scientific literature to assist scientists in drug discovery. It is currently used by 16 of the top 20 pharmaceutical companies and in more than 4,300 research centers. Founded in 2015 by Liran Belenzon and Elvis Wianda, the Toronto-based company has grown to between 201 and 500 employees and operates with a remote-first model.
Looking forward, BenchSci continues to focus on expanding its AI capabilities and partnerships. The company recently extended its agreement with the pharmaceutical company Merck for an additional two years, supporting its preclinical disease biology research. In June 2023, BenchSci raised US$69.6 million in a Series D funding round. The company is also engaging with the tech community through events like the BenchSpark Hackathon, a competition to build a prototype AI co-scientist, and by organizing panel discussions on topics such as scaling a company beyond early-stage funding.
- Generation Investment Management
- Inovia Capital
- TCV
- F-Prime Capital
- Gradient Ventures
- Golden Ventures
- Real Ventures
- Afore Capital
- Radical Ventures
- Co-Founder, Tom Leung
- Co-Founder, David Qixiang Chen
- Co-Founder, Elvis Wianda
- Co-Founder, Liran Belenzon
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is BenchSci worth joining?
This is a personal decision that depends on your career goals, financial situation, and evaluation of the company's growth prospects and culture. To help assess the financial side, platforms like Prospect can model the potential value of your equity compensation and compare it to other opportunities.
What should I do with my BenchSci stock?
Managing your startup stock involves creating a strategy for exercising options and selling shares that aligns with your financial goals and minimizes taxes. Prospect offers tools to build customized option exercise strategies based on your specific equity and tax situation.
Can you sell BenchSci stock?
Since BenchSci is a private company, you cannot sell your stock on a public exchange; selling is typically restricted to specific events like a tender offer or after an IPO. When an opportunity to sell arises, tender offer tools can help you decide how much to sell and which shares are the most tax-optimal.
How can I find the value of my BenchSci stock?
The value of private company stock is typically determined by its 409A valuation, which is an independent appraisal of its fair market value (FMV). For a forward-looking estimate, predictive models can project the future value of your shares using data similar to what venture capitalists use.
What is BenchSci's equity worth?
The total worth of your BenchSci equity depends on the number of shares you own and the company's current valuation, which fluctuates as the company grows. You can use Prospect to upload your equity grants and get a clear picture of your holdings' potential future value and tax implications.
What is BenchSci's stock ticker symbol?
Because BenchSci is a private company, it does not have a stock ticker symbol, as those are only assigned to publicly traded companies. Until an IPO occurs, your equity is managed privately, and tools from Prospect can help you navigate the complexities of pre-IPO stock.
Can I buy or sell BenchSci stock?
As a private company, BenchSci stock is not available for purchase by the general public, and selling is restricted to company-approved liquidity events like tender offers. If you are an employee with equity, platforms like Prospect can help you plan for these events and make informed decisions when they occur.
What is the criteria to buy or invest in BenchSci stock?
Investing in a private company like BenchSci is typically limited to accredited investors in organized funding rounds or employees receiving equity compensation. If you are an employee, understanding the value of your grant is crucial, and resources like Prospect Equity can provide clarity.
